<DOC>
	<DOCNO>NCT02494999</DOCNO>
	<brief_summary>In order evaluate immunogenicity safety 13-valent pneumococcal conjugate vaccine produce Beijing Minhai Biotechnology Co. , Ltd. , randomize , double-blind , parallel-controlled phase III clinical trial plan conduct healthy infant age 3-6 month China .</brief_summary>
	<brief_title>A Phase III Clinical Trial 13-valent Pneumococcal Conjugate Vaccine Healthy Infants</brief_title>
	<detailed_description>There two arm . 900 healthy infant age 3-6 month randomly assign ( 1:1 ) receive experimental vaccine comparator vaccine Month 0,1 2 ( primary vaccination ) . All receive fourth dose booster vaccination Month 9 .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Aged 3 6 month old day inclusion Subjects ' legal guardian able understand sign inform consent Subjects ' legal guardian comply requirement protocol Subjects temperature &lt; =37.0°C axillary set Preterm infant low birth weight infant Any administration history pneumococcal polysaccharide vaccine pneumococcal conjugate vaccine A medical history cultureconfirmed invasive disease cause Streptococcus pneumonia Subject allergic history serious adverse reaction history vaccination allergy , hive , difficulty breathing , angioedema abdominal pain Subject congenital malformation , developmental disorder , genetic defect severe malnutrition Subject epilepsy , history seizure convulsion , family history mental illness Known suspect immune deficiency immune suppression Diagnosed coagulation abnormality ( clot factor deficiency , coagulation disorder , platelet disorder ) significant bruise blood clot disorder Had immunosuppressive therapy , cytotoxic therapy , inhaled corticosteroid ( include allergic rhinitis corticosteroid spray treatment , acute uncomplicated dermatitis surface corticosteroid therapy ) past 6 month Any prior administration blood product last 3 month Any prior administration attenuate live vaccine last 14 day Any prior administration subunit inactivate vaccine last 7 day Any acute infection serious infection need systemic antibiotic antiviral treatment last 7 day Any fever temperature &gt; =38.0°C axillary setting last 3 day Any factor judge investigator , may interfere subject 's compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>pneumococcal conjugate vaccine</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>safety</keyword>
</DOC>